Novo executive on new approval: "Ozempic is unequivocally the strongest product in its class"
Novo Nordisk has gained a clear competitive edge, after the FDA approved the addition of new cardiovascular data to the enclosed information sheet for its diabetes drug Ozempic, believes Novo Nordisk's research director Mads Krogsgaard Thomsen.
There can no longer be any doubt about which GLP-1 analogue diabetes treatment is best.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
